常山药业(300255) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 525,781,826.50, a 20.54% increase year-on-year[8] - Net profit attributable to shareholders increased by 29.28% to CNY 70,957,328.87 compared to the same period last year[8] - Basic earnings per share rose by 33.33% to CNY 0.08[8] - Total operating revenue for the current period reached ¥525,781,826.50, an increase of 20.5% compared to ¥436,193,853.25 in the previous period[53] - Net profit for the current period was ¥70,301,795.02, representing a 29.5% increase from ¥54,237,565.19 in the previous period[56] - The total comprehensive income for the current period was ¥72,267,845.21, compared to ¥45,313,897.55 in the previous period, showing a significant increase of 59.6%[60] - The total comprehensive income for the current period was ¥78,709,598.32, up from ¥54,571,569.91 in the previous period[66] - Net profit for the current period was ¥202,475,165.19, compared to ¥161,169,675.84 in the previous period, representing a growth of 25.6%[79] Assets and Liabilities - Total assets increased by 4.97% to CNY 4,035,875,603.02 compared to the end of the previous year[8] - Total liabilities amounted to ¥1,345,900,837.11, up from ¥1,321,811,944.11, indicating a growth of around 1.8%[39] - Current liabilities increased to ¥1,112,139,440.56 from ¥1,087,225,065.94, showing a rise of about 2.3%[39] - The total assets amounted to ¥3,844,836,970.34, remaining stable compared to the previous reporting period[101] - Total liabilities amounted to CNY 1,321,811,944.11, with current liabilities at CNY 1,087,225,065.94[108] - The total assets of the company were CNY 3,920,311,564.94, with non-current assets at CNY 1,355,388,161.77[114] Cash Flow - Cash flow from operating activities showed a significant decline, with a net cash outflow of CNY -195,091,069.12, a decrease of 618.23% compared to the previous year[8] - Net cash inflow from operating activities decreased by 618.23% compared to the same period last year, mainly due to increased cash payments related to operating activities[22] - Cash flow from operating activities generated a net outflow of ¥195,091,069.12, compared to a net inflow of ¥37,645,343.75 in the previous period[85] - Net cash flow from operating activities was -¥138,149,438.86, compared to -¥3,987,833.92 in the previous period, indicating a significant decline[94] Shareholder Information - The total number of shareholders at the end of the reporting period was 28,086[12] - The largest shareholder, Gao Shuhua, holds 35.69% of the shares, amounting to 333,644,728 shares[12] Expenses - Sales expenses increased by 40.90% compared to the same period last year, primarily due to increased marketing expenses[22] - Research and development expenses for the current period were ¥38,973,977.21, up from ¥31,137,192.57, reflecting a growth of 25.2%[53] - The company’s sales expenses rose to ¥259,976,993.84, reflecting a 37% increase from ¥189,661,423.92 in the previous period[63] - Financial expenses for the current period were ¥9,233,747.09, which is a 45.5% increase from ¥6,362,291.90 in the previous period[63] Government Subsidies - The company received government subsidies amounting to CNY 7,926,708.03 during the reporting period[8] - Other income increased by 95.75% compared to the same period last year, mainly due to an increase in government subsidies related to operating activities[22] Inventory and Receivables - Accounts receivable decreased by 51.65% compared to the beginning of the period, mainly due to a reduction in the company's bill settlement business[22] - Prepayments increased by 81.21% compared to the beginning of the period, primarily due to prepaid goods and market development expenses[22] - Inventory increased from CNY 1,083,154,292.88 at the end of 2018 to CNY 1,352,992,132.71 by September 30, 2019[33] - The pre-receivable amount increased to ¥252,275,168.80 from ¥223,454,598.51, a rise of 12.9%[52]